RE:Obesity drugs From the transcripts of yesterday d CC
In fact, our total number of unique patients hit an all-time high at the end of calendar 2023, up 13% year-over-year for the month of December. Allow me for a moment now to remind people about the EGRIFTA SV's benefits and marketing position, given the noise about weight loss drugs and particularly GLP-1s, where recent clinical research has shown them to also induce muscle mass reduction.
As the only medication of its kind approved in the US and designed specifically for adults with HIV, EGRIFTA SV's unique mechanism of action decreases excess visceral abdominal fat while actually increasing lean body mass.
This is especially important people with HIV where muscle loss can be a serious issue. Furthermore, healthcare providers are increasingly recognizing that excess visceral abdominal fat is a medical condition that can lead to very serious health consequences if left untreated.
We welcome this shift in understanding and diagnosis that should support patient identification and market demand for EGRIFTA SV. Before we move on, I want to address the recent update concerning our sBLA for the F8 formulation of Tesamorelin and take a moment to review the facts and timelines.